Back to results

Thalamic Deep Brain Stimulation for Secondary Dystonia in Children and Young Adults (DBSVop)

Primary Purpose

Dystonia

Status

Completed

Phase

Not Applicable

Locations

United States

Study Type

Interventional

Intervention

Activa PC Primary Cell Neurostimulator - (Model 37601)

Activa RC Rechargeable Neurostimulator - (Model 37612)

Activa SC Single Cell Neurostimulator (Models 37602/37603)

DBS Lead - (Model 3387

DBS Extension - (Models 37085/6)

Patient Programmer - (Model 37642)

Test Stimulator - (Model 3625)

N'Vision Clinician Programmer - (Model 8840)

N'Vision Software Application Card - (Model 8870)

About this trial

This is an interventional treatment trial for Dystonia

Eligibility Criteria

7 Years - 25 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Ability to give informed consent or assent for the study
Dystonia symptoms that are sufficiently severe, in spite of best medical therapy, to warrant surgical implantation of deep brain stimulators according to standard clinical criteria
Age 7-25
Stable doses of anti-dystonia medications (such as levodopa, baclofen, or diazepam) for at least 30 days prior to baseline assessment
If patient receives botulinum toxin injections, patient should be on a stable injection regimen
Intact thalamic anatomy as determined by standard clinical MRI

Exclusion Criteria:

Pregnancy or breast feeding
Major comorbidity increasing the risk of surgery (severe hypertension, severe diabetes, or need for chronic anticoagulation other than aspirin)
Inability to comply with study follow-up visits
Any prior intracranial surgery
Uncontrolled epilepsy
Immunocompromised
Has an active infection
Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) to treat a chronic condition
Has an existing implanted neurostimulator or cardiac pacemaker.
Dystonia caused by known genetic mutation in any DYT genes

Sites / Locations

University of California San Francisco Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

DBS active

Arm Description

All participants will be enrolled in DBS placement and active stimulation. The following components will be used: Activa PC Primary Cell Neurostimulator - (Model 37601) Activa RC Rechargeable Neurostimulator - (Model 37612) Activa SC Single Cell Neurostimulator (Models 37602 and 37603) DBS Lead - (Model 3387) DBS Extension - (Models 37085/6) Patient Programmer - (Model 37642) Test Stimulator - (Model 3625) N'Vision Clinician Programmer - (Model 8840) N'Vision Software Application Card - (Model 8870)

Outcomes

Primary Outcome Measures

Change From Baseline in Burke-Fahn-Marsden Dystonia Rating Scale

Rating scale that measures movement and disability related to dystonia, range 0-120 motor, 0-30 disability , higher number indicates more severe dystonia Change from Baseline in Burke-Fahn-Marsden Dystonia Rating Scale

Percent Change in Pediatric Quality of Life Inventory (PedsQL)

Quality of life measure, scored 0-100, larger scores indicate greater hinderance (ie. lower quality of life)

Change in Barry Albright Dystonia Rating Scale

Severity scale for secondary dystonia, range 0-32, higher scores indicates more severe dystonia

Change in Blinded Burke-Fahn-Marsden Dystonia Rating Scale

Rating scale that measures movement and disability related to dystonia, range 0-120 motor, 0-30 disability , higher number indicates more severe dystonia. These ratings were carried out retroactively by a neurologist who was unfamiliar with the four study participants and who had no knowledge of their unblinded scores.

Secondary Outcome Measures

Change in Modified Ashworth Scale - Upper Limbs

Measure of spasticity, range 0-32, higher values indicate more spasticity

Change in Diadochokinetic Syllable Rates

Articulation, range (min 6- no upper limit), longer times indicate less articulation/more difficulty with speech

Children's Memory Scale

Will include the following subtests: Memory for Faces, Dot Locations, and Digit Span

Change in Behavioral Assessment System, 3rd Edition: Self Report of Personality

Mood and behavior assessment, main use as a screening tool for depression.

Change in Modified Ashworth Scale Spasticity Ratings - Lower Limbs

This scale is used to measure spasticity, which is a velocity-dependent increase in muscle stretch reflexes associated with increased muscle tone as a component of upper motor neuron syndrome. It is scored 0-4 with higher scores indicating greater severity.

Change in Kaufman Brief Intelligence Test - Second Addition

Kaufman Brief Intelligence Test Second Edition (KBIT-2) is a brief measure of verbal and nonverbal intelligence used with individuals ages 4 through 90 years, raw scores 0 - unlimited, with higher scores indicating higher ability.

Change in Burke-Fahn-Marsden Dystonia Disability Subscale

This scale is a measurement of quality of life related to dystonia, with lower scores indicating greater quality of life and high scores indicating more hinderance. It is scored 0-100.

Change in Modified Unified Parkinson's Disease Rating Scale - Second Edition

This scale is a measurement of quality of life related to dystonia, with lower scores indicating greater quality of life and high scores indicating more hinderance. It is scored 0-199

Full Information

NCT ID

NCT03078816

First Posted

April 26, 2016

Last Updated

September 14, 2020

Sponsor

University of California, San Francisco

1. Study Identification

Unique Protocol Identification Number

NCT03078816

Brief Title

Thalamic Deep Brain Stimulation for Secondary Dystonia in Children and Young Adults

Acronym

DBSVop

Official Title

Thalamic Deep Brain Stimulation for Secondary Dystonia in Children and Young Adults

Study Type

Interventional

2. Study Status

Record Verification Date

September 2020

Overall Recruitment Status

Completed

Study Start Date

March 3, 2017 (Actual)

Primary Completion Date

July 24, 2019 (Actual)

Study Completion Date

July 24, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

University of California, San Francisco

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

Yes

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

Dystonia is a movement disorder seen in both children and adults that is characterized by "sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or both." Secondary dystonia is far more common in pediatric populations than primary dystonia, and far more recalcitrant to standard pharmacologic and surgical treatments including Deep Brain Stimulation (DBS). There exists a large unmet need to develop new therapeutics, treatment strategies, and outcome measures for pediatric secondary dystonia. The investigators are proposing to investigate the ventralis oralis posterior nucleus (Vop) of the thalamus as a new target for DBS in secondary dystonia. Prior to the development of DBS, the main surgical treatment of dystonia was thalamotomy. Although there were many different targets in the thalamus, often done in staged procedures, the most common and successful targeted nuclei was the Vop, which is traditionally thought to be the pallidal receiving area. Previous lesioning of Vop produced improvements in dystonia but intolerable side effects, especially when implanted bilaterally. However, given that secondary dystonia patients were often reported to have superior results to primary dystonia it is reasonable to believe that if the side effects can be modulated, that targeting of the Vop nucleus with DBS could be a viable alternative to Globus Pallidus interna (GPi). Given that Deep Brain Stimulation is a treatment that is inherently adjustable, it is conceivable that settings on the Deep Brain Stimulation could be adjusted to allow for clinical benefit with minimal side effects. Indeed, there have been several scattered successful case reports attesting to this possibility.

Detailed Description

Dystonia is a movement disorder seen in both children and adults that is characterized by "sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or both." Secondary dystonia has evolved to refer to dystonia resulting from damage to the nervous system or degenerative disease processes. While primary dystonia is generally thought to arise from genetic causes, secondary dystonias have a variety of causes including perinatal injuries (cerebral palsy), central nervous system infections, traumatic brain injuries, and many different metabolic, neurodegenerative, and mitochondrial conditions. Secondary dystonia is far more common in pediatric populations than primary dystonia, and far more recalcitrant to standard pharmacologic and surgical treatments including Deep Brain Stimulation. Given that most treatments for dystonia are developed for primary dystonia and then applied to secondary dystonia, it is not surprising that this effectiveness gap exists. Thus, there exists a large unmet need to develop new therapeutics, treatment strategies, and outcome measures for pediatric secondary dystonia. Deep Brain Stimulation (DBS) is one such therapeutic intervention that has potential to improve secondary dystonia. DBS is a surgical treatment for several different movement disorders that evolved from functional stereotactic neurosurgery techniques initially used to lesion specific deep brain structures. While Essential Tremor and Idiopathic Parkinson's Disease have predictable and consistent response rates to DBS in carefully selected patients, response rates of dystonia have been much more inconsistent. One predictor of success has been the presence of DYT-1 mutation, the most common known genetic cause of primary dystonia. Success rates in DYT-1 dystonia are consistently high with reductions in dystonia typically greater than 80%. However, the results in secondary dystonia have been much more modest and inconsistent. A recent meta-analysis found that on average, dystonia symptoms as measured by common rating scales improve 23% following DBS for dystonic cerebral palsy (the most common cause of secondary dystonia), however there are frequent cases of non-responders. Additionally, there have been very few examination, radiological or laboratory predictors of good response to DBS, except for genetic confirmation of DYT-119. However, across both primary and secondary dystonia, younger age at the time of surgery (less than 21 years old) and shorter duration of symptoms (less than 15 years) have been shown to be the most likely predictive factors for a good postoperative outcome. This has led many to suggest that DBS should be offered earlier in the course of intractable dystonia, prior to the development of permanent complications such as orthopedic contractures. Thus, we are setting an upper age limit of 25 to account for the concern that earlier implantation leads to improved outcomes. The lower age limit of 7 reflects the fact that the current humanitarian exemption for DBS for dystonia currently goes down to age 7. Thus, there exists a need to both improve patient selection as well as application of DBS for secondary dystonia in children.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Dystonia

7. Study Design

Primary Purpose

Treatment

Study Phase

Not Applicable

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

5 (Actual)

8. Arms, Groups, and Interventions

Arm Title

DBS active

Arm Type

Experimental

Arm Description

Intervention Type

Device

Intervention Name(s)

Activa PC Primary Cell Neurostimulator - (Model 37601)

Intervention Description